You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 生物科技股大漲 發改委印發十四五生物經濟發展規劃
格隆匯5月11日丨再鼎醫藥大漲近15%領銜走高,康方生物、科濟藥業、雲頂新耀、藥明生物均漲超9%,歌禮制藥、金斯瑞生物科技等多數個股漲幅超6%以上。國家發改委印發十四五生物經濟發展規劃提出,強化企業創新主體地位,要發揮生物領域龍頭企業引領支撐作用,引導大企業向產業鏈上下游開放科技創新、供應鏈、金融服務等資源,推動與中小企業融通創新。圍繞生物醫藥、生物農業、生物製造等規模大、影響廣的重點領域,鼓勵生物創新企業深耕細分領域,厚植髮展優勢,培育成為具有全球競爭力的單項冠軍。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account